A Plain Language Summary of the SAVANNAH Study: Savolitinib Plus Osimertinib in Patients with EGFR-mutated Advanced Non-Small Cell Lung Cancer with MET Overexpression And/or Amplification Whose Cancer Had Grown or Spread on Osimertinib.